MN-166 - Revision history

Lazy at 02:58, 24 February 2025

2025-02-24T02:58:12Z

← Older revision		Revision as of 19:58, 23 February 2025
Line 4:		Line 4:
	\|used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder		\|used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder
	\|clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder		\|clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder
	\|~~common_side_effects~~=~~Not specified; has been used~~ in ~~Japan~~ with a ~~good post~~-~~marketing safety profile~~		\|clinical_trial_explanation=In glioblastoma, a Phase 1b/2a trial evaluated MN-166 in combination with temozolomide (TMZ), showing it was safe and well-tolerated. Progression-Free Survival at 6 months (PFS6) was 44% in newly diagnosed patients and 31% in recurrent cases, with the latter improving over historical controls. MN-166 is also in a Phase 2b/3 trial for ALS (COMBAT-ALS), where interim analysis suggests it may slow disease progression. The trial is ongoing, with top-line data expected in 2026.
	\|~~OS_with~~=~~Not specified~~		\|common_side_effects=Generally well-tolerated; possible mild gastrointestinal issues and fatigue. No unexpected adverse effects in clinical trials.
	\|~~OS_without~~=~~Not specified~~		\|OS_with=Under investigation; preliminary results suggest potential for improved survival in glioblastoma patients.
	\|PFS_with=~~Not specified~~		\|PFS_with=Phase 1b/2a data shows PFS6 of 44% in newly diagnosed glioblastoma and 31% in recurrent cases.
	\|~~PFS_without~~=~~Not specified~~		\|usefulness_rating=4
	\|~~usefulness_rating~~=3 (~~awaiting research~~)		\|usefulness_explanation=MN-166 shows promise in glioblastoma when combined with temozolomide, with clinical trials indicating improved progression-free survival. It has demonstrated potential in slowing neurodegenerative disease progression (ALS, MS, DCM) and is undergoing further clinical validation.
	\|toxicity_level=1		\|toxicity_level=1
	\|notes=MN-166 (Ibudilast) is a small molecule ~~compound~~ that inhibits PDE4 and inflammatory cytokines including MIF. It ~~is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and~~ has been ~~in use~~ in Japan for over 20 years. ~~The drug is in various stages of clinical development in other regions~~, ~~including Phase 3~~ for ~~ALS and DCM~~, ~~and Phase 2 for glioblastoma and substance use disorder.~~		\|notes=MN-166 (Ibudilast) is an anti-inflammatory small molecule that inhibits PDE4 and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It has been used in Japan for over 20 years with a well-documented safety profile. In glioblastoma, its ability to enhance TMZ effectiveness makes it a promising candidate for further research. Additionally, an NIH-funded Expanded Access Protocol is providing MN-166 to ALS patients to evaluate its impact on neurofilament light levels, a key biomarker for neuronal damage.
	~~\|links=https://medicinova.com/clinical~~-~~development/core/mn~~-166~~/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-~~to~~-Meet-with-U-S-FDA-~~to~~-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html~~, ~~https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-~~a~~-Phase-2~~.~~html~~
	\|treatment_category=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|~~toxicity_explanation~~=MN-166 (~~Ibudilast~~) ~~is generally regarded as having a low toxicity level due to its long~~-~~term use in Japan for other conditions~~. On a ~~scale of 1 to 5,~~ with ~~5 being the most toxic, it is rated at 1~~. ~~This means that the drug~~ is generally well-tolerated and ~~the risk of severe side~~ effects ~~is relatively low. However, as MN-166 (Ibudilast) is still undergoing~~ clinical trials ~~for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option~~.		\|links=* [MediciNova's Clinical Development](https://medicinova.com/clinical-development/core/mn-166/)
	\|overview=MN-166 (Ibudilast) is an anti-inflammatory ~~small molecule with FDA approval~~ in Japan for ~~conditions like~~ post-stroke complications and ~~bronchial~~ asthma~~, currently undergoing~~ late-stage ~~clinical~~ trials for ALS, ~~Progressive~~ MS, and DCM ~~in other regions. With a good safety profile~~ and ~~low toxicity,~~ it is also ~~being explored experimentally~~ for ~~glioblastoma,~~ Long COVID, and substance use disorder, ~~although its overall usefulness rating remains at 3 pending further research~~.}}		* [Phase 1b/2a Clinical Trial in Glioblastoma](https://www.biospace.com/medicinova-announces-data-from-phase-1b-2a-clinical-trial-of-mn-166-ibudilast-in-glioblastoma-patients-at-the-american-society-of-clinical-oncology-asco-annual-meeting-2024)
			* [COMBAT-ALS Trial](https://alsnewstoday.com/news/mn-166-ibudilast-slowing-als-progression-trial-data-suggest/)
			* [NIH-funded Expanded Access Clinical Trial](https://medicinova.gcs-web.com/news-releases/news-release-details/medicinova-support-nih-funded-expanded-access-clinical-trial)
			\|toxicity_explanation=MN-166 has a well-documented safety profile with low toxicity. It is generally well-tolerated, though mild gastrointestinal symptoms and fatigue may occur. No unexpected adverse effects have been reported in glioblastoma or ALS clinical trials.
			\|overview=MN-166 (Ibudilast) is a PDE4 inhibitor with anti-inflammatory properties approved in Japan for post-stroke complications and asthma. It is in late-stage trials for ALS, MS, and DCM, and early trials for glioblastoma suggest it may improve progression-free survival when combined with temozolomide. Its neuroprotective properties are also under investigation for Long COVID and substance use disorder, making it a versatile candidate for repurposed drug therapies.
			}}

Lazy at 08:23, 18 January 2025

2025-01-18T08:23:55Z

← Older revision		Revision as of 01:23, 18 January 2025
Line 15:		Line 15:
	\|treatment_category=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_explanation=MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.		\|toxicity_explanation=MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.
	}}		\|overview=MN-166 (Ibudilast) is an anti-inflammatory small molecule with FDA approval in Japan for conditions like post-stroke complications and bronchial asthma, currently undergoing late-stage clinical trials for ALS, Progressive MS, and DCM in other regions. With a good safety profile and low toxicity, it is also being explored experimentally for glioblastoma, Long COVID, and substance use disorder, although its overall usefulness rating remains at 3 pending further research.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:37:13Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:37, 12 November 2024
Line 13:		Line 13:
	\|notes=MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.		\|notes=MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.
	\|links=https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html		\|links=https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_explanation=MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.		\|toxicity_explanation=MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.
	}}		}}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:43Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 10:		Line 10:
	\|PFS_without=Not specified		\|PFS_without=Not specified
	\|usefulness_rating=3 (awaiting research)		\|usefulness_rating=3 (awaiting research)
	\|toxicity_level=~~Low based on its long-term use in Japan for other conditions~~		\|toxicity_level=1
	\|notes=MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.		\|notes=MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.
	\|links=https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html		\|links=https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
			\|toxicity_explanation=MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=MN-166 (Ibudilast) |FDA_approval=Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions |used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder |clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder |commo..."

2024-03-27T06:04:59Z

Created page with "{{TreatmentInfo |drug_name=MN-166 (Ibudilast) |FDA_approval=Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions |used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder |clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder |commo..."

New page

{{TreatmentInfo
|drug_name=MN-166 (Ibudilast)
|FDA_approval=Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions
|used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder
|clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder
|common_side_effects=Not specified; has been used in Japan with a good post-marketing safety profile
|OS_with=Not specified
|OS_without=Not specified
|PFS_with=Not specified
|PFS_without=Not specified
|usefulness_rating=3 (awaiting research)
|toxicity_level=Low based on its long-term use in Japan for other conditions
|notes=MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.
|links=https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html
|category=Repurposed Drugs
}}